Endocrine Abstracts

The purpose of the study was to assess the functional state of the kidneys in patients with type 2 diabetes, depending on hypoglycemic therapy.

Material and research methods: 60 patients with type 2 diabetes with CKD. The mean age of the patients was 54±2.5 years, the experience of diabetes was 11.7±0.18, the mean Hb1C was 9.1%, and the mean fasting glycemia was 11.2 mmol/l. The patients were divided into 2 groups: group 1-30 patients on the iSGLT-2+ metformin, group 2–30 patients on the iDPP-4+metformin. The observation period was 6 months.

Research results and discussion: In patients with type 2 diabetes with diabetic nephropathy (CKD 2, A2), iSGLT 2 after 6 months of observation effectively reduced the level of glycated hemoglobin (Hb1C) by 1.0% and fasting plasma glucose was 8.4 mmol/l, in patients taking iDPP-4 10 mmol/l. A significant improvement in GFR is observed after 6 months of taking iSGLT-2, at the 1st visit 69.2±0.08 ml/min per 1.7 m² after 6 months 82.7±2.85 ml/min per 1.7 m². According to our results, IGLT2 reduces the risk of progression of albuminuria, 68% of patients reported MAU – 32.01 mg/day at the 1st visit, after 6 months 28.5 mg/day.

Conclusions: The use of iSGLT-2 in DM2 patients with nephropathy not only improves glycemic control and slows down the development of diabetic kidney damage (reduces the rate of increase in albuminuria and improves GFR).